Will a contrarian leader be good for the Food and Drug Administration? Which ATTR-CM drug will have the best launch? And what are the hosts making for their holiday dinners?
We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. STAT’s FDA reporter Lizzy Lawrence joins us to discuss her profile of Marty Makary, Trump’s nominee for FDA commissioner. Then, we discuss the results of Vertex’s latest pain drug trial, the medication launches to watch in 2025, and present our burning questions for the biopharma industry.
To read the profile of Makary, go here; for more on a top FDA official’s departure, go here; to learn about Vertex’s pain data disappointment, go here; and for Adam’s 2025 predictions, go here.
Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, TuneIn, or wherever you get your podcasts.